177 related articles for article (PubMed ID: 27913464)
1. New challenges in evaluating anemia in older persons in the era of molecular testing.
Steensma DP
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):67-73. PubMed ID: 27913464
[TBL] [Abstract][Full Text] [Related]
2. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
[TBL] [Abstract][Full Text] [Related]
3. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
4. Clonal Hematopoiesis of Indeterminate Potential.
Heuser M; Thol F; Ganser A
Dtsch Arztebl Int; 2016 May; 113(18):317-22. PubMed ID: 27215596
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
Bejar R
Curr Hematol Malig Rep; 2015 Sep; 10(3):282-91. PubMed ID: 26126599
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of somatic mutation in unexplained blood cytopenia.
Malcovati L; Gallì A; Travaglino E; Ambaglio I; Rizzo E; Molteni E; Elena C; Ferretti VV; Catricalà S; Bono E; Todisco G; Bianchessi A; Rumi E; Zibellini S; Pietra D; Boveri E; Camaschella C; Toniolo D; Papaemmanuil E; Ogawa S; Cazzola M
Blood; 2017 Jun; 129(25):3371-3378. PubMed ID: 28424163
[TBL] [Abstract][Full Text] [Related]
7. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.
Steensma DP
Blood; 2018 Oct; 132(16):1657-1663. PubMed ID: 30185432
[TBL] [Abstract][Full Text] [Related]
8. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes.
Foran JM; Shammo JM
Am J Med; 2012 Jul; 125(7 Suppl):S6-13. PubMed ID: 22735753
[TBL] [Abstract][Full Text] [Related]
9. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.
Rauw J; Wells RA; Chesney A; Reis M; Zhang L; Buckstein R
Leuk Res; 2011 Oct; 35(10):1335-8. PubMed ID: 21704372
[TBL] [Abstract][Full Text] [Related]
10. Aplastic anemia and clonal evolution: germ line and somatic genetics.
Shimamura A
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):74-82. PubMed ID: 27913465
[TBL] [Abstract][Full Text] [Related]
11. Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology.
Bastida JM; López-Godino O; Vicente-Sánchez A; Bonanad-Boix S; Xicoy-Cirici B; Hernández-Sánchez JM; Such E; Cervera J; Caballero-Berrocal JC; López-Cadenas F; Arnao-Herráiz M; Rodríguez I; Llopis-Calatayud I; Jiménez MJ; Del Cañizo-Roldán MC; Díez-Campelo M
Int J Lab Hematol; 2019 Feb; 41(1):109-117. PubMed ID: 30290085
[TBL] [Abstract][Full Text] [Related]
12. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
13. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathologic challenges of clonal cytopenia of undetermined significance.
Weinberg OK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():82-85. PubMed ID: 34288451
[TBL] [Abstract][Full Text] [Related]
15. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
16. Implications of molecular genetic diversity in myelodysplastic syndromes.
Bejar R
Curr Opin Hematol; 2017 Mar; 24(2):73-78. PubMed ID: 27875374
[TBL] [Abstract][Full Text] [Related]
17. Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms.
Makishima H
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101189. PubMed ID: 33038978
[TBL] [Abstract][Full Text] [Related]
18. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
Iwasaki T; Murakami M; Sugisaki C; Sobue S; Ohashi H; Asano H; Suzuki M; Nakamura S; Ito M; Murate T
Pathol Int; 2008 Jun; 58(6):353-60. PubMed ID: 18477214
[TBL] [Abstract][Full Text] [Related]
19. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
[TBL] [Abstract][Full Text] [Related]
20. Where Does Morphology Fit in Myelodysplastic Syndrome Diagnosis in the Era of Molecular Testing?
Giagounidis A; Haase S
Hematol Oncol Clin North Am; 2020 Apr; 34(2):321-331. PubMed ID: 32089213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
